NasdaqCM:CORTPharmaceuticals
Did FDA Uncertainty Around Relacorilant Just Shift Corcept Therapeutics' (CORT) Investment Narrative?
Earlier this week, Corcept Therapeutics faced heightened scrutiny as investors reacted to the upcoming U.S. FDA decision on relacorilant, a drug application supported by one successful and one unsuccessful late-stage trial, while analysts reassessed the company’s revenue outlook.
This tension highlights how a single high-stakes regulatory call on relacorilant could meaningfully affect Corcept’s efforts to broaden its business beyond its current core franchise.
Now we’ll examine how the FDA...